SCHEMBL26032098

SCHEMBL26032098

CCCCCCCCCCCCCCCC(=O)NCCOCCNC(=O)c1cc(OCCNC(=O)CCOCCOCCOCCOCCNC(=O)CCN2C(=O)CC(C(C)C)C2=O)cc(C(=O)NCCOCCNC(=O)CCCCCCCCCCCCCCC)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 17/20 0.39
CNR2 P34972 16/20 0.39
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26032095 1.00 CNR1 (0.39) CNR1CNR2HPGDHTTSMN1; SMN2
SCHEMBL26032100 0.93 CNR1 (0.35) CNR1CNR2SMN1; SMN2
SCHEMBL26032226 0.89 HPGD (0.43) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032028 0.82 HPGD (0.40) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032030 0.82 HPGD (0.40) HPGDHTTSMN1; SMN2HDAC3HDAC4
SCHEMBL26032035 0.82 GLP1R (0.52) HPGDHTTSMN1; SMN2
SCHEMBL26032070 0.82 GLP1R (0.52) HPGDHTTSMN1; SMN2
SCHEMBL26032037 0.82 GLP1R (0.52) HPGDHTTSMN1; SMN2
SCHEMBL13814445 0.81 HPGD (0.48) CNR1CNR2HPGDHTTSMN1; SMN2
SCHEMBL14750406 0.81 SMN1; SMN2 (0.39) HPGDHTTSMN1; SMN2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 CNR1 4167/4885CNR2 4501/4885HPGD 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.